Current Hematologic Malignancy Reports
ISSN:1558-8211

Current Hematologic Malignancy Reports

CURR HEMATOL MALIG R
学科领域:医学
是否预警:不在预警名单内
是否OA:
录用周期:>12周,或约稿
新锐分区:医学3区
年发文量:23
影响因子:3.3
JCR分区:Q2

基本信息

他的杂志旨在提供清晰,有见地,平衡的国际专家的贡献,审查最重要的,最近发表的临床发现有关的诊断,治疗,管理和预防血液恶性肿瘤。我们通过任命国际权威人士担任部分编辑的关键主题领域,如白血病,淋巴瘤,骨髓瘤,和T细胞和其他淋巴增生性恶性肿瘤的目标。而版块编辑则会选择一些主题,让顶尖专家为这些主题撰写全面的评论文章,这些文章强调新的发展和最近发表的重要论文,并通过注释参考文献列表突出显示。一个国际编辑委员会审查年度目录,建议他们国家/地区特别感兴趣的文章,并确保主题是最新的,包括新兴的研究。还提供了该领域知名人士的评论。
1558-8211SCIE/Scopus收录
3.3
3.9
2026年3月发布
点击查看历史分区趋势    >
大类学科小类学科Top期刊综述期刊
医学3区
ONCOLOGY 肿瘤学
3区
HEMATOLOGY 血液学
3区
N/A
WOS期刊SCI分区  2024-2025最新升级版
按JIF指标学科分区收集子录JIF分区JIF排名百分位
学科:HEMATOLOGY
SCIE
Q2
28/99
学科:ONCOLOGY
SCIE
Q2
123/328
按JCR指标学科分区收集子录JCR分区JCR排名百分位
学科:HEMATOLOGY
SCIE
Q3
62/100
学科:ONCOLOGY
SCIE
Q3
234/328
28
23
1%0>12周,或约稿-ONCOLOGY-HEMATOLOGY
0%
时间预警情况
2026年03月发布的新锐学术版不在预警名单中
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
0.00%18.39%-
CiteScore:5.90
SJR:1.123
SNIP:0.728
学科类别分区排名百分位
大类:Medicine
小类:Hematology
Q1
31 / 142
大类:Medicine
小类:Oncology
Q2
121 / 415
大类:Medicine
小类:Cancer Research
Q2
95 / 233

期刊高被引文献

Targeting BTK in CLL: Beyond Ibrutinib
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00512-0
Relapsed T Cell ALL: Current Approaches and New Directions
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00501-3
The Rationale for Immunotherapy in Myeloproliferative Neoplasms
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00527-7
The Role of PI3K Inhibition in Lymphoid Malignancies
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00540-w
Solitary Plasmacytoma: a Review of Diagnosis and Management
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00499-8
Induced Pluripotent Stem Cell (iPSC)–Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00528-6
Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00538-4
Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00523-x
Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00502-2
Treatment-Free Remission in CML: the US Perspective
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-0496-8
IMiDs New and Old
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00536-6
Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00508-w
Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00545-5
Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00511-1
Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00543-7
Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00525-9
Is There a Role for Dose Modification of TKI Therapy in CML?
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00524-w
Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-0495-9
Circulating Tumor Cells: State-of-the-art Update on Technologies and Clinical Applications
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00531-x
Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00533-9
Health-Related Quality of Life and Treatment of Older Adults with Acute Myeloid Leukemia: a Young International Society of Geriatric Oncology Review Paper
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00552-6
What Does Chronic Myeloid Leukaemia Tell Us About Other Leukaemias?
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00555-3
Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come?
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00510-2
Pathogen-Specific T Cells Beyond CMV, EBV and Adenovirus
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00521-z
Integrative Approaches to Managing Myeloproliferative Neoplasms: the Role of Nutrition, Exercise, and Psychological Interventions
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00516-w
Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00505-z
Targeting Translation of mRNA as a Therapeutic Strategy in Cancer
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00530-y
The Emerging Role of Liquid Biopsies in Lymphoproliferative Disorders
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-0493-y
Overcoming Challenges in Process Development of Cellular Therapies
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00529-5
Correction to: Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00506-y
Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00556-2
Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00518-8
Graft Versus Host Disease Clinical Trials: Is it Time for Patients Centered Outcomes to Be the Primary Objective?
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-0494-x
Multi-Specific CAR Targeting to Prevent Antigen Escape
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00537-5
Driving the CAR to the Bone Marrow Transplant Program
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00544-6
The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00549-1
Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00507-x
Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00546-4
Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00542-8
Chromatin-Remodeled State in Lymphoma
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00541-9
Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00500-4
Early Management of CML
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00550-8
Development and Significance of Mouse Models in Lymphoma Research
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00504-0
Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00553-5
Emerging Role of Integrative Medicine in Hematologic Malignancies: a Literature Review and Update on Current Trends in Complementary Medical Practices in Hematologic Cancers
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00526-8
Mutation-Driven Therapy in MDS
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00554-4
Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00519-7
Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now?
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-0492-z
Towards Automated Manufacturing for Cell Therapies
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00522-y
The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS)
来源期刊:Current Hematologic Malignancy ReportsDOI:10.1007/s11899-019-00547-3

相关文章

2026年3月发布
大类学科小类学科Top期刊综述期刊
医学3区
ONCOLOGY 肿瘤学
3区
HEMATOLOGY 血液学
3区
N/A
2025年3月升级版
大类学科小类学科Top期刊综述期刊
医学3区
HEMATOLOGY 血液学
3区
ONCOLOGY 肿瘤学
3区
2023年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学3区
HEMATOLOGY 血液学
3区
ONCOLOGY 肿瘤学
4区